Table 1.
Baseline characteristics of the 16 patients with NAFLD complicated by T2DM
| Factors | n = 16 |
|---|---|
| Age (years) | 53 (41–62) |
| Gender (men/women) | 9/7 |
| Body weight (kg) | 74.4 (72.0–86.9) |
| BMI (kg/m2) | 29.6 (27.4–33.7) |
| Platelets (×103/μL) | 231 (183–285) |
| AST (U/L) | 40 (37–50) |
| ALT (U/L) | 67 (44–81) |
| γ‐GTP (U/L) | 66 (55–114) |
| eGFR (mL/min/1.73m2) | 67 (61–94) |
| Uric acid (mg/dl) | 5.3 (5.0–6.9) |
| LDL cholesterol (mg/dL) | 101 (84–141) |
| HDL cholesterol (mg/dL) | 45 (43–51) |
| Triglyceride (mg/dL) | 175 (122–246) |
| Plasma glucose (mg/dL) | 123 (119–138) |
| HbA1c (%) | 6.9 (6.6–7.3) |
| Insulin (μU/mL) | 19.8 (15.4–32.8) |
| HOMA‐IR | 6.6 (4.3–11.2) |
| Method for the diagnosis of NAFLD | |
| Ultrasonography only | 12 (75.0%) |
| Histopathological diagnosis | 4 (25.0%) |
| Diabetes treatment prior to semaglutide | |
| Diet/exercise only (without antidiabetic drugs) | 11 (68.8%) |
| Anti‐diabetic drugs | 5 (31.3%) |
| Biguanides | 3 (18.8%) |
| SGLT2‐Is | 1 (6.3%) |
| DPP4‐Is | 3 (18.8%) |
| Insulin | 2 (12.5%) |
| Anti‐dyslipidemic drugs | 9 (56.3%) |
| Statins | 7 (43.8%) |
| Ferritin (ng/mL) | 135.2 (101.3–259.6) |
| Type IV collagen 7 s (ng/mL) | 4.1 (3.6–5.7) |
| WFA+‐M2BP (C.O.I.) | 0.85 (0.68–1.12) |
| FIB‐4 index | 1.42 (0.69–3.25) |
| CAP (dB/m) | 344 (312–354) |
| LSM (kPa) | 5.5 (5.1–16.0) |
Data are presented as numbers (percentages) or medians (interquartile ranges).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; DPP4‐Is, dipeptidyl peptidase‐4 inhibitors; eGFR, estimated glomerular filtration rate; FIB‐4, fibrosis‐4; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; HOMA‐IR, homeostasis model assessment‐insulin resistance; LDL, low‐density lipoprotein; LSM, liver stiffness measurement; NAFLD, non‐alcoholic fatty liver disease; SGLT2‐Is, sodium glucose cotransporter 2 inhibitors; T2DM, type 2 diabetes mellitus; WFA+‐M2BP, Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein; γ‐GTP, gamma glutamyl transpeptidase.